Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis

The American Journal of Medicine

Volumn 98, Issue 3, 1995, Pages 249-256

  Catanzaro, Antonino ^a   Galgiani, John N ^b   Levine, Bernard E ^c   Sharkey Mathis, Patricia K ^d   Fierer, Joshua ^e   Stevens, David A ^f   Chapman, Stanley W ^g   Cloud, Gretchen ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; FLUCONAZOLE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; COMPLEMENT FIXATION; DRUG EFFICACY; DRUG SAFETY; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; IMMUNODIFFUSION; LEG CRAMP; LIBIDO; LUNG INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SKIN DISEASE; SOFT TISSUE INFECTION;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COCCIDIOIDOMYCOSIS; FLUCONAZOLE; HUMAN; LUNG DISEASES, FUNGAL; MIDDLE AGE; RECURRENCE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT OUTCOME;

EID: 0028899863     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)80371-4     Document Type: Article

References (24)

1. Coccidioidomycosis--United States, 1991-1992.
2. State of the art: coccidioidomycosis. Part I
3. State of the art: coccidioidomycosis. Part II
4. Amphotericin B in the treatment of coccidioidomycosis
5. Ketoconazole for treatment of chronic pulmonary coccidioidomycosis
6. Ketoconazole for treatment of disseminated coccidioidomycosis
7. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400-and 800-mg doses and observations at higher doses
8. Ketoconazole treatment of nonprimary coccidioidomycosis. Evaluation of 60 patients during three years of study
9. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis
10. Pharmacology and toxicity of high-dose ketoconazole.
11. Oral Azole Drugs as Systemic Antifungal Therapy
12. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
13. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations
14. Itraconazole in the treatment of coccidioidomycosis
15. Fluconazole, a new antifungal agent
16. Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. PanAmerican Study Group
17. Fluconazole in the treatment of persistent coccidioidomycosis
18. Treatment of coccidioidomycosis with ketoconazole: an evaluation utilizing a new scoring system
19. Exclusions, losses to follow-up withdrawals in clinical trials
20. Nonparametric Estimation from Incomplete Observations
21. Regression models and life tables
22. Hypercalcemia in disseminated coccidioidomycosis
23. Cellular immune response in coccidioidomycosis
24. In vitro assays of cellular immunity in progressive coccidioidomycosis: evaluation of suppression with parasitic-phase antigen